Citation map · Study

SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs

16 references·3 citing·38 second hop

FromToDepth

this work references cited by second hop

References

2006Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies206 cited
2006Patients’ attitudes towards and experiences of generic drug substitution in Norway153 cited
2010Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications153 cited
2009Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance150 cited
2006Customers’ and physicians’ opinions of and experiences with generic substitution during the first year in Finland119 cited
2010Ongoing pharmaceutical reforms in France108 cited
2009Soft regulations in pharmaceutical policy making97 cited
2010Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe?93 cited
2007International comparison of generic medicine prices86 cited
2008Recent National and Regional Drug Reforms in Sweden85 cited
2009Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment73 cited
2008Price control as a strategy for pharmaceutical cost containment—What has been achieved in Norway in the period 1994–2004?71 cited
2008Enhancing the rational use of new medicines across European health care systems71 cited
2008

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

Insight into recent reforms and initiatives in Austria: implications for key stakeholders

70 cited

2010Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications69 cited

2008Tier 4 Drugs and the Fraying of the Social Compact67 cited

Cited by

2012Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach60 cited
2021Evidence-based public policy making for medicines across countries: findings and implications for the future55 cited
2019Pricing of oral generic cancer medicines in 25 European countries; findings and implications48 cited